In Vivo deletion of CAR resulted in high bone mass phenotypes in male mice

Journal of Cellular Physiology

Volumn 229, Issue 5, 2014, Pages 561-571

  Cho, Hwa Young ^a,d   Jung, Ju Yeon ^a   Park, Hyojung ^a   Yang, Jae Yeon ^b   Jung, Solip ^a   An, Jee Hyun ^a,b   Cho, Sun Wook ^a   Kim, Sang Wan ^a   Kim, Seong Yeon ^a   Kim, Jung Eun ^c   Park, Young Joo ^a,b   Shin, Chan Soo ^a,b  

^a Seoul National University College of Medicine   (South Korea)

^b Seoul National University   (South Korea)

^c Kyungpook National University School of Medicine   (South Korea)

^d Armed Forces Capital Hospital   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; CALCITRIOL; CONSTITUTIVE ANDROSTANE RECEPTOR; CYTOCHROME P450 2B10; CYTOCHROME P450 2B9; MESSENGER RNA; TESTOSTERONE; UNCLASSIFIED DRUG; XENOBIOTIC AGENT;

ADULT; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BONE DENSITY; BONE MASS; CALVARIA; CONTROLLED STUDY; DOWN REGULATION; EMBRYO; GENE DELETION; IN VIVO STUDY; LIVER; MALE; MICRO-COMPUTED TOMOGRAPHY; MOUSE; NEWBORN; NONHUMAN; ORCHIECTOMY; OSTEOBLAST; OSTEOCLAST; PHENOTYPE; PRECURSOR; PRIMARY CULTURE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; TESTOSTERONE METABOLISM; TIBIA; TRABECULAR BONE; WILD TYPE;

ALKALINE PHOSPHATASE; ANIMALS; ARYL HYDROCARBON HYDROXYLASES; BONE DENSITY; CELLS, CULTURED; DIHYDROXYCHOLECALCIFEROLS; FEMALE; GENE EXPRESSION REGULATION; MACROPHAGES; MALE; MICE; MICE, KNOCKOUT; ORCHIECTOMY; RECEPTORS, CYTOPLASMIC AND NUCLEAR; TESTOSTERONE;

EID: 84892633120     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.24478     Document Type: Article

References (50)

1. Anderson FH, Francis RM, Faulkner K. 1996. Androgen supplementation in eugonadal men with osteoporosis-effects of 6 months of treatment on bone mineral density and cardiovascular risk factors. Bone 18:171-177.
2. Benz DJ, Haussler MR, Thomas MA, Speelman B, Komm BS. 1991. High-affinity androgen binding and androgenic regulation of alpha 1(I)-procollagen and transforming growth factor-beta steady state messenger ribonucleic acid levels in human osteoblast-like osteosarcoma cells. Endocrinology 128:2723-2730.
3. Blumberg B, Sabbagh W Jr, Juguilon H, Bolado J Jr, van Meter CM, Ong ES, Evans RM. 1998. SXR, a novel steroid and xenobiotic-sensing nuclear receptor. Genes Dev 12:3195-3205.
4. Buckley MJ, Banes AJ, Levin LG, Sumpio BE, Sato M, Jordan R, Gilbert J, Link GW, Tran Son, Tay R. 1988. Osteoblasts increase their rate of division and align in response to cyclic, mechanical tension in vitro. Bone Miner 4:225-236.
5. Colvard DS, Eriksen EF, Keeting PE, Wilson EM, Lubahn DB, French FS, Riggs BL, Spelsberg TC. 1989. Identification of androgen receptors in normal human osteoblast-like cells. Proc Natl Acad Sci USA 86:854-857.
6. di Masi A, De Marinis E, Ascenzi P, Marino M. 2009. Nuclear receptors CAR and PXR: Molecular, functional, and biomedical aspects. Mol Aspects Med 30:297-343.
7. Forman BM, Tzameli I, Choi HS, Chen J, Simha D, Seol W, Evans RM, Moore DD. 1998. Androstane metabolites bind to and deactivate the nuclear receptor CAR-beta. Nature 395:612-615.
8. Francis RM, Peacock M, Aaron JE, Selby PL, Taylor GA, Thompson J, Marshall DH, Horsman A. 1986. Osteoporosis in hypogonadal men: Role of decreased plasma 1, 25-dihydroxyvitamin D, calcium malabsorption, and low bone formation. Bone 7:261-268.
9. Genuth SM, Klein L, Rabinovich S, King KC. 1972. Osteomalacia accompanying chronic anticonvulsant therapy. J Clin Endocrinol Metab 35:378-386.
10. Girasole G, Jilka RL, Passeri G, Boswell S, Boder G, Williams DC, Manolagas SC. 1992. 17 beta-estradiol inhibits interleukin-6 production by bone marrow-derived stromal cells and osteoblasts in vitro: A potential mechanism for the antiosteoporotic effect of estrogens. J Clin Invest 89:883-891.
11. Guo D, Sarkar J, Suino-Powell K, Xu Y, Matsumoto K, Jia Y, Yu S, Khare S, Haldar K, Rao MS, Foreman JE, Monga SP, Peters JM, Xu HE, Reddy JK. 2007. Induction of nuclear translocation of constitutive androstane receptor by peroxisome proliferator-activated receptor alpha synthetic ligands in mouse liver. J Biol Chem 282:36766-36776.
12. Huang W, Zhang J, Chua SS, Qatanani M, Han Y, Granata R, Moore DD. 2003. Induction of bilirubin clearance by the constitutive androstane receptor (CAR). Proc Natl Acad Sci USA 100:4156-4161.
13. Ioannides C. 1996. Cytochromes P450: Metabolic and toxicological aspects. Boca Raton, FL, USA: CRC Press. pp 172-185
14. Jarukamjorn K, Sakuma T, Nemoto N. 2002. Sexual dimorphic expression of mouse hepatic CYP2B: Alterations during development or after hypophysectomy. Biochem Pharmacol 63:2037-2041.
15. Kasra M, Grynpas MD. 1995. The effects of androgens on the mechanical properties of primate bone. Bone 17:265-270.
16. Kawamoto T, Sueyoshi T, Zelko I, Moore R, Washburn K, Negishi M. 1999. Phenobarbital-responsive nuclear translocation of the receptor CAR in induction of the CYP2B gene. Mol Cell Biol 19:6318-6322.
17. Kelly PJ, Pocock NA, Sambrook PN, Eisman JA. 1990. Dietary calcium, sex hormones, and bone mineral density in men. Br Med J 300:1361-1364.
18. Kodama S, Koike C, Negishi M, Yamamoto Y. 2004. Nuclear receptors CAR and PXR cross talk with FOXO1 to regulate genes that encode drug-metabolizing and gluconeogenic enzymes. Mol Cell Biol 24:7931-7940.
19. Maglich JM, Lobe DC, Moore JT. 2009. The nuclear receptor CAR (NR1I3) regulates serum triglyceride levels under conditions of metabolic stress. J Lipid Res 50:439-445.
20. Masson D, Qatanani M, Sberna AL, Xiao R, Pais de Barros JP, Grober J, Deckert V, Athias A, Gambert P, Lagrost L, Moore DD, Assem M. 2008. Activation of the constitutive androstane receptor decreases HDL in wild-type and human apoA-I transgenic mice. J Lipid Res 49:1682-1691.
21. Mawer EB, Davies M. 2001. Vitamin D nutrition and bone disease in adults. Rev Endocr Metab Disord 2:153-164.
22. Min G, Kim H, Bae Y, Petz L, Kemper JK. 2002. Inhibitory cross-talk between estrogen receptor (ER) and constitutively activated androstane receptor (CAR). CAR inhibits ER-mediated signaling pathway by squelching p160 coactivators. J Biol Chem 277:34626-34633.
23. Moreau A, Maurel P, Vilarem MJ, Pascussi JM. 2007. Constitutive androstane receptor-vitamin D receptor crosstalk: Consequence on CYP24 gene expression. Biochem Biophys Res Commun 360:76-82.
24. Moverare S, Venken K, Eriksson AL, Andersson N, Skrtic S, Wergedal J, Mohan S, Salmon P, Bouillon R, Gustafsson JA, Vanderschueren D, Ohlsson C. 2003. Differential effects on bone of estrogen receptor alpha and androgen receptor activation in orchidectomized adult male mice. Proc Natl Acad Sci USA 100:13573-13578.
25. Murphy S, Khaw KT, Cassidy A, Compston JE. 1993. Sex hormones and bone mineral density in elderly men. Bone Miner 20:133-140.
26. Nishimura M, Naito S, Yokoi T. 2004. Tissue-specific mRNA expression profiles of human nuclear receptor subfamilies. Drug Metab Pharmacokinet 19:135-149.
27. Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR. 1987. Bone histomorphometry: Standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 2:595-610.
28. Park YJ, Qatanani M, Chua SS, LaRey JL, Johnson SA, Watanabe M, Moore DD, Lee YK. 2008. Loss of orphan receptor small heterodimer partner sensitizes mice to liver injury from obstructive cholestasis. Hepatology 47:1578-1586.
29. Pascussi JM, Gerbal-Chaloin S, Fabre JM, Maurel P, Vilarem MJ. 2000. Dexamethasone enhances constitutive androstane receptor expression in human hepatocytes: Consequences on cytochrome P450 gene regulation. Mol Pharmacol 58:1441-1450.
30. Quarles LD. 2008. Endocrine functions of bone in mineral metabolism regulation. J Clin Invest 118:3820-3828.
31. Raisz LG. 1988. Local and systemic factors in the pathogenesis of osteoporosis. N Engl J Med 318:818-828.
32. Raisz LG. 1997. The osteoporosis revolution. Ann Intern Med 126:458-462.
33. Rickard DJ, Hofbauer LC, Bonde SK, Gori F, Spelsberg TC, Riggs BL. 1998. Bone morphogenetic protein-6 production in human osteoblastic cell lines. Selective regulation by estrogen. J Clin Invest 101:413-422.
34. Riggs BL, Melton LJ III. 1986. Involutional osteoporosis. N Engl J Med 314:1676-1686.
35. Rosenfeld JM, Vargas R Jr, Xie W, Evans RM. 2003. Genetic profiling defines the xenobiotic gene network controlled by the nuclear receptor pregnane X receptor. Mol Endocrinol 17:1268-1282.
36. Schweikert HU, Rulf W, Niederle N, Schafer HE, Keck E, Kruck F. 1980. Testosterone metabolism in human bone. Acta Endocrinol (Copenh) 95:258-264.
37. Shibata T, Shira-Ishi A, Sato T, Masaki T, Masuda A, Hishiya A, Ishikura N, Higashi S, Uchida Y, Saito MO, Ito M, Ogata E, Watanabe K, Ikeda K. 2002. Vitamin D hormone inhibits osteoclastogenesis in vivo by decreasing the pool of osteoclast precursors in bone marrow. J Bone Miner Res 17:622-629.
38. Shinoda Y, Yamaguchi M, Ogata N, Akune T, Kubota N, Yamauchi T, Terauchi Y, Kadowaki T, Takeuchi Y, Fukumoto S, Ikeda T, Hoshi K, Chung UI, Nakamura K, Kawaguchi H. 2006. Regulation of bone formation by adiponectin through autocrine/paracrine and endocrine pathways. J Cell Biochem 99:196-208.
39. Sueyoshi T, Kawamoto T, Zelko I, Honkakoski P, Negishi M. 1999. The repressed nuclear receptor CAR responds to phenobarbital in activating the human CYP2B6 gene. J Biol Chem 274:6043-6046.
40. Uitterlinden AG, Fang Y, Bergink AP, van Meurs JB, van Leeuwen HP, Pols HA. 2002. The role of vitamin D receptor gene polymorphisms in bone biology. Mol Cell Endocrinol 197:15-21.
41. Urano T, Usui T, Shiraki M, Ouchi Y, Inoue S. 2009. Association of a single nucleotide polymorphism in the constitutive androstane receptor gene with bone mineral density. Geriatr Gerontol Int 9:235-241.
42. Vanderschueren D, Vandenput L, Boonen S, Lindberg MK, Bouillon R, Ohlsson C. 2004. Androgens and bone. Endocr Rev 25:389-425.
43. Vestergaard P. 2005. Epilepsy, osteoporosis and fracture risk-A meta-analysis. Acta Neurol Scand 112:277-286.
44. Wada T, Gao J, Xie W. 2009. PXR and CAR in energy metabolism. Trends Endocrinol Metab 20:273-279.
45. Wei P, Zhang J, Egan-Hafley M, Liang S, Moore DD. 2000. The nuclear receptor CAR mediates specific xenobiotic induction of drug metabolism. Nature 407:920-923.
46. Willson TM, Kliewer SA. 2002. PXR, CAR and drug metabolism. Nat Rev Drug Discov 1:259-266.
47. Wit JM, Camacho-Hubner C. 2011. Endocrine regulation of longitudinal bone growth. Endocr Dev 21:30-41.
48. Yanase T, Suzuki S, Goto K, Nomura M, Okabe T, Takayanagi R, Nawata H. 2003. Aromatase in bone: Roles of Vitamin D3 and androgens. J Steroid Biochem Mol Biol 86:393-397.
49. Yang NN, Bryant HU, Hardikar S, Sato M, Galvin RJ, Glasebrook AL, Termine JD. 1996. Estrogen and raloxifene stimulate transforming growth factor-beta 3 gene expression in rat bone: A potential mechanism for estrogen- or raloxifene-mediated bone maintenance. Endocrinology 137:2075-2084.
50. Zerwekh JE, Oz OK. 2007. Estrogen and androgen play distinct roles in bone turnover in male mice before and after reaching sexual maturity. Bone 40:553.